ENTERA BIO LTD. (ENTX) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Lose.
15/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinENTX / S&P 59.46% / 15.20% |
LoseENTX / S&P -100.00% / 15.00% |
LoseENTX / S&P 34.62% / 50.40% |
| 2026-Q10/3 |
LoseENTX / S&P -42.78% / -4.33% |
LoseENTX / S&P -100.00% / 11.30% |
LoseENTX / S&P 3.85% / 27.70% |
| 2025-Q40/3 |
LoseENTX / S&P 1.04% / 2.65% |
LoseENTX / S&P -76.80% / 9.00% |
LoseENTX / S&P 4.00% / 13.40% |
| 2025-Q31/3 |
LoseENTX / S&P 1.05% / 8.12% |
WinENTX / S&P 25.25% / 4.61% |
LoseENTX / S&P -3.85% / 13.45% |
| 2025-Q22/3 |
WinENTX / S&P 11.76% / 10.94% |
WinENTX / S&P 191.23% / 4.83% |
LoseENTX / S&P 0.00% / 10.63% |
| 2025-Q10/3 |
LoseENTX / S&P -19.81% / -4.27% |
LoseENTX / S&P ENTX unavailable / 4.98% |
LoseENTX / S&P -7.14% / 10.57% |
| 2024-Q41/3 |
WinENTX / S&P 11.58% / 2.41% |
LoseENTX / S&P ENTX unavailable / 5.25% |
LoseENTX / S&P -19.35% / 6.15% |
| 2024-Q31/3 |
LoseENTX / S&P 3.26% / 5.89% |
WinENTX / S&P 607.14% / 5.89% |
LoseENTX / S&P -23.53% / 6.11% |
| 2024-Q22/3 |
WinENTX / S&P 10.18% / 4.28% |
WinENTX / S&P 159.09% / 5.38% |
LoseENTX / S&P -29.73% / 5.12% |
| 2024-Q11/3 |
WinENTX / S&P 178.33% / 10.56% |
LoseENTX / S&P -100.00% / 5.71% |
LoseENTX / S&P -30.00% / 5.59% |
| 2023-Q40/3 |
LoseENTX / S&P -17.24% / 11.69% |
LoseENTX / S&P -100.00% / 6.81% |
LoseENTX / S&P -31.11% / 7.78% |
| 2023-Q30/3 |
LoseENTX / S&P -14.00% / -3.27% |
LoseENTX / S&P -95.09% / 7.52% |
LoseENTX / S&P -32.00% / -5.03% |
| 2023-Q20/3 |
LoseENTX / S&P -27.33% / 8.74% |
LoseENTX / S&P -94.72% / 9.50% |
LoseENTX / S&P -26.00% / -8.57% |
| 2023-Q11/3 |
WinENTX / S&P 58.90% / 7.50% |
LoseENTX / S&P -86.31% / 10.77% |
LoseENTX / S&P -18.37% / -15.69% |
| 2022-Q40/3 |
LoseENTX / S&P -29.81% / 7.56% |
LoseENTX / S&P -76.53% / 11.88% |
LoseENTX / S&P ENTX unavailable / -17.99% |
| 2022-Q30/3 |
LoseENTX / S&P -21.80% / -4.88% |
LoseENTX / S&P ENTX unavailable / 13.47% |
LoseENTX / S&P ENTX unavailable / -1.41% |
| 2022-Q20/3 |
LoseENTX / S&P -53.66% / -16.10% |
LoseENTX / S&P ENTX unavailable / 13.71% |
LoseENTX / S&P ENTX unavailable / 11.04% |
| 2022-Q11/3 |
WinENTX / S&P 1.95% / -4.60% |
LoseENTX / S&P ENTX unavailable / 15.97% |
LoseENTX / S&P ENTX unavailable / 42.23% |
| 2021-Q40/3 |
LoseENTX / S&P -40.23% / 11.03% |
LoseENTX / S&P ENTX unavailable / 15.00% |
LoseENTX / S&P ENTX unavailable / 96.40% |
| 2021-Q30/3 |
LoseENTX / S&P -21.24% / 0.58% |
LoseENTX / S&P ENTX unavailable / 10.77% |
LoseENTX / S&P ENTX unavailable / 69.42% |
| 2021-Q21/3 |
WinENTX / S&P 56.96% / 8.55% |
LoseENTX / S&P ENTX unavailable / 6.58% |
LoseENTX / S&P ENTX unavailable / 51.81% |
| 2021-Q11/3 |
WinENTX / S&P 252.78% / 6.17% |
LoseENTX / S&P ENTX unavailable / -1.06% |
LoseENTX / S&P ENTX unavailable / 7.39% |
| 2020-Q40/3 |
LoseENTX / S&P -12.90% / 12.15% |
LoseENTX / S&P ENTX unavailable / -3.72% |
LoseENTX / S&P ENTX unavailable / -33.42% |
| 2020-Q30/3 |
LoseENTX / S&P -32.61% / 8.93% |
LoseENTX / S&P ENTX unavailable / -2.04% |
LoseENTX / S&P ENTX unavailable / -27.10% |
| 2020-Q20/3 |
LoseENTX / S&P -10.59% / 20.54% |
LoseENTX / S&P ENTX unavailable / -0.46% |
LoseENTX / S&P ENTX unavailable / -27.11% |
| 2020-Q11/3 |
WinENTX / S&P -3.83% / -19.60% |
LoseENTX / S&P ENTX unavailable / 3.47% |
LoseENTX / S&P ENTX unavailable / -14.75% |
| 2019-Q40/3 |
LoseENTX / S&P -14.06% / 9.07% |
LoseENTX / S&P ENTX unavailable / 5.36% |
LoseENTX / S&P ENTX unavailable / 2.99% |
| 2019-Q30/3 |
LoseENTX / S&P -27.41% / 1.70% |
LoseENTX / S&P ENTX unavailable / 5.02% |
LoseENTX / S&P ENTX unavailable / 0.21% |
| 2019-Q20/3 |
LoseENTX / S&P -20.69% / 4.30% |
LoseENTX / S&P ENTX unavailable / 6.64% |
LoseENTX / S&P ENTX unavailable / 8.65% |
| 2019-Q11/3 |
WinENTX / S&P 41.80% / 13.65% |
LoseENTX / S&P ENTX unavailable / 8.12% |
LoseENTX / S&P ENTX unavailable / 14.29% |
| 2018-Q40/3 |
LoseENTX / S&P -47.50% / -13.52% |
LoseENTX / S&P ENTX unavailable / 9.05% |
LoseENTX / S&P ENTX unavailable / 18.23% |
| 2018-Q30/3 |
LoseENTX / S&P -7.78% / 7.71% |
LoseENTX / S&P ENTX unavailable / 10.21% |
LoseENTX / S&P ENTX unavailable / 19.06% |
| 2018-Q20/3 |
LoseENTX / S&P ENTX unavailable / 3.43% |
LoseENTX / S&P ENTX unavailable / 9.03% |
LoseENTX / S&P ENTX unavailable / 14.46% |
| 2018-Q10/3 |
LoseENTX / S&P ENTX unavailable / -0.76% |
LoseENTX / S&P ENTX unavailable / 7.68% |
LoseENTX / S&P ENTX unavailable / 12.46% |
| 2017-Q40/3 |
LoseENTX / S&P ENTX unavailable / 6.64% |
LoseENTX / S&P ENTX unavailable / 7.03% |
LoseENTX / S&P ENTX unavailable / 13.82% |
| 2017-Q30/3 |
LoseENTX / S&P ENTX unavailable / 4.48% |
LoseENTX / S&P ENTX unavailable / 5.68% |
LoseENTX / S&P ENTX unavailable / 17.57% |
| 2017-Q20/3 |
LoseENTX / S&P ENTX unavailable / 3.09% |
LoseENTX / S&P ENTX unavailable / 4.83% |
LoseENTX / S&P ENTX unavailable / 17.74% |
| 2017-Q10/3 |
LoseENTX / S&P ENTX unavailable / 6.07% |
LoseENTX / S&P ENTX unavailable / 3.67% |
LoseENTX / S&P ENTX unavailable / 13.32% |
| 2016-Q40/3 |
LoseENTX / S&P ENTX unavailable / 3.82% |
LoseENTX / S&P ENTX unavailable / 2.09% |
LoseENTX / S&P ENTX unavailable / 7.05% |
| 2016-Q30/3 |
LoseENTX / S&P ENTX unavailable / 3.85% |
LoseENTX / S&P ENTX unavailable / 0.20% |
LoseENTX / S&P ENTX unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ENTX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 59.59% | 20.78% |
| Annualized return | 59.59% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ENTX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -40.31% | 83.14% |
| Annualized return | -9.81% | 12.86% |
10Y · 2018-06-28 to 2026-08-27
| Metric | ENTX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -50.96% | 319.30% |
| Annualized return | -6.88% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |